Amylyx Pharmaceuticals, Inc. Common Stock (AMLX)
NASDAQ · Healthcare
Amylyx Pharmaceuticals, Inc. Common Stock Operating Income 2021–2025
Amylyx Pharmaceuticals, Inc. Common Stock annual/quarterly operating income history and growth rate from 2021 to 2025. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Amylyx Pharmaceuticals, Inc. Common Stock operating income for the quarter ending September 30, 2025 was -36.0 M, a 52.38% decrease year-over-year.
- Amylyx Pharmaceuticals, Inc. Common Stock operating income for the twelve months ending September 30, 2025 was -192.3 M, a 20.60% increase year-over-year.
- Amylyx Pharmaceuticals, Inc. Common Stock annual operating income for 2025 was -153.3 M, a 51.29% decrease from 2024.
- Amylyx Pharmaceuticals, Inc. Common Stock annual operating income for 2024 was -314.7 M, a 911.12% decrease from 2023.
- Amylyx Pharmaceuticals, Inc. Common Stock annual operating income for 2023 was 38.8 M, a 119.27% decrease from 2022.
- Amylyx Pharmaceuticals, Inc. Common Stock annual operating income for 2022 was -201.3 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Amylyx Pharmaceuticals, Inc. Common Stock Operating Income — FAQ
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) operating income over the last 5 years — annual and quarterly figures with year-over-year growth and charts.
What is Amylyx Pharmaceuticals, Inc. Common Stock's operating income?
Amylyx Pharmaceuticals, Inc. Common Stock (AMLX) reported operating income of -$153M for fiscal 2025.
Where can I see AMLX's operating income history?
The chart and table above show Amylyx Pharmaceuticals, Inc. Common Stock's operating income by year and by quarter, including the growth rate.